Beleave Inc. (CSE: BE) is pleased to announce that it will begin a collaborative research project with Dr. Lesley Campbell, associate professor in the Department of Chemistry and Biology at Ryerson University, with the goal of developing new Cannabis sativa breeding tools for Beleave, Inc. This research project aims to expand existing work on Campbell’s quantitative genetic models into new precision breeding efforts in Cannabis. These advanced genetic models have already identified novel genetic traits involved in the expression of cannabidiol (CBD). This project will further solidify the collaborative industrial-academic partnership between the Campbell lab and Beleave.
By combining proteomic and genetic tools, this new project aims to further identify and characterize the genetic traits in Cannabis that control the inheritance and production of cannabinoids including but not limited to CBD, which is a non-psychoactive cannabinoid that has been shown to display tremendous potential for several clinical indications. Once models of cannabinoid inheritance have been fully characterized, this will allow Beleave to design breeding programs that make use of these newly identified molecular factors to more tightly control cannabinoid production. “This tool provides an exciting and unique way of generating product IP for plant strains developed and commercialized under the Beleave brand, which can be protected by patenting newly identified genetic and proteomic markers”, commented Beleave CEO, Roger Ferreira.
Whereas Beleave’s expertise in Cannabis growing will be employed to produce plants, the Campbell lab will assess and analyse the plant material, identifying plants with unique chemical signatures. “Allowing scientists and researchers to observe and participate in the development of essential technical skills and in the practice of discovering new intellectual property will be incredibly important for this emerging industry”, remarked Dr. Campbell. A $72,000 Collaborative Research and Development (CRD) grant has been awarded by the Natural Sciences and Engineering Research Council (NSERC) will help cover research salaries and laboratory materials for the project.
About Beleave
Beleave, Inc. is a biotech company committed to becoming a licensed producer under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR“). Beleave’s wholly-owned subsidiary First Access Medical Inc. (“FAM“) has applied for a license to cultivate and sell medical marihuana pursuant to the ACMPR. As of the date hereof, FAM has successfully advanced past the review stage, and has been issued an affirmation letter from Health Canada prior to a request for a pre-licensing inspection. Beleave’s purpose-built facility is located near Hamilton, Ontario.
In the interest of full disclosure, we call the reader’s attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.
Read Next
